MedTrace Logo

Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma

NCT04305548 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-03-27

No results posted yet for this study

Summary

Prospective, uncontrolled, investigator-initiated, phase II clinical study to explore the activity of trabectedin in a population of patients aged ≥16 years with progressive, advanced (locally advanced or metastatic)

Conditions

  • Mesenchymal Chondrosarcoma

Interventions

DRUG

Trabectedin

Treatment with trabectedin: 1.5 mg/m² - 1.3 mg/m² (at investigator's discretion, with a top-dose of 2.6 total mg per cycle), given in 24-hour continuous infusion

Sponsors & Collaborators

  • PharmaMar

    collaborator INDUSTRY

  • Italian Sarcoma Group

    lead NETWORK

Principal Investigators

  • Silvia Stacchiotti, MD · Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-14
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04305548 on ClinicalTrials.gov